BioMarin Pharma (BMRN) to Acquire Prosensa (RNA) for $17.75/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
Prosensa (RNA) CVRs Appear Achievable, Says Credit Suisse; PT Raised to $20 (Earlier)
November 25, 2014 1:20 PM ESTCredit Suisse maintained a Neutral rating on Prosensa (NASDAQ: RNA) and raised its price target to $20.00 (from $9.00). Yesterday BioMarin Pharma (NASDAQ: BMRN) announced a deal to acquire the company for $17.75 per share plus two CVRs worth $80 million... More
BioMarin (BMRN) Price Target Raised to $103 at RBC
November 25, 2014 7:42 AM ESTRBC Capital maintained an Outperform rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and raised its price target to $103.00 (from $87.00). Yesterday BioMarin announced a deal to acquire Prosensa Holding N.V. (NASDAQ: RNA).
Analyst Michael J. Yee said, "After further follow-up... More
RBC Capital Comments on BioMarin (BMRN) Following Prosensa (RNA) Deal
November 24, 2014 8:34 AM ESTRBC Capital maintained an Outperform rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a price target of $87. Earlier BioMarin announced a deal to acquire Prosensa (Nasdaq: RNA) for $680 million plus milestone payments. Analyst Michael J. Yee thinks BioMarin stock could be weak today, but overall he remains positive, and it doesn't change his view on BioMarin's pipeline.
"Reasons BMRN investors may view the deal with skepticism: 1) BMRN is viewed as a mid-cap more... More
Sarepta Therapeutics (SRPT) Gains on BioMarin, Prosensa Deal
November 24, 2014 7:26 AM ESTSarepta Therapeutics (NASDAQ: SRPT) gained pre-market Monday after peer Prosensa Holding N.V. (NASDAQ: RNA) and BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced a deal in which BioMarin will offer to purchase all of the outstanding ordinary shares of Prosensa for $17.75 per share.
... More